Welcome to Astor Scientific

New collections added! Learn more

TribioScience  |  SKU: TBI4826-5MG

Sitravatinib, Multikinase inhibitor / Immuno-oncology agent (TBI4826)

$90.00
Shipping calculated at checkout.


Care information

Display general product information or specific product information using metafields.

Delivery and Shipping

Add some general information about your delivery and shipping policies.

Payment & Security

Payment methods

  • American Express
  • Apple Pay
  • Diners Club
  • Discover
  • Google Pay
  • Mastercard
  • PayPal
  • Shop Pay
  • Venmo
  • Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.


Product Description


Product Reviews

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
TribioScience

Sitravatinib, Multikinase inhibitor / Immuno-oncology agent (TBI4826)

From $90.00

Description

Product Details

Formal Name: 1-N’-[3-Fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

Alternate Names: MGCD516

Molecular Formula: C33H29F2N5O4S

Formula Weight: 629.68

CAS Number: 1123837-84-2

Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to at least 25 mg/ml) or in Ethanol (up to at least 25 mg/ml)

Storage: -20°C

Stability: ≥ 1 year.

Applications

Multikinase inhibitor / Immuno-oncology agent

Functions

Sitravatinib is a broad spectrum receptor tyrosine kinase inhibitor. Its targets include Axl, c-Met, PDGFR, VEGFR, Ephrin receptor family, and FLT3 among others at nanomolar levels. Sitravatinib has been tested in mouse models of sarcoma and showed better efficacy than both imatinib and crizotinib. Because of its unique kinase inhibition profile (especially that of TAM receptors), it has been used to restore response to anti-PD-1 therapy (nivolumab) in NSCLC patients. Sitravatinib was able to significantly alter the immunosuppressive tumor microenvironment in three preclinical tumor models to enhance the effects of PD-1 blockade therapy.

Application Procedures

First dissolved in DMSO (up to at least 25 mg/ml) or in Ethanol (up to at least 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month.

Option

  • 5 MG
  • 25 MG
View product
close
close
I have a question
sparkles
close
product
Hello! I am very interested in this product.
gift
Special Deal!
sparkles